Exelixis, Inc. (EXEL), a mid-sized pharmaceutical, is a strong buy, forecast to double in the next five years, with potential to do much better than that.
Analysis
EXEL is intriguing on several counts. First, it came through a simple screen for ((A)) FDA-approved drugs, ((B)) positive cash flow from operating activities, ((C)) rated as a consensus “buy” among analysts cited by Yahoo, ((D)) often beats Street estimates for quarterly earnings, and finally, ((E)) EXEL is expected to maintain a near-term annual growth rate of 46%.
After the market drops of last week,